Joincare Pharmaceutical Group Industry Co., Ltd.

简体中文 | English







Latest Financial Statements

Well-known Brand

Inhalation Preparation

R&D Strength

Subsidiary Company

ABOUT US

Joincare (Joincare Pharmaceutical Group Industry Co., Ltd) was founded in 1992, and the company located the headquarter in Shenzhen Special Economic Zone. With years of steady operation and fast development, Joincare has become a pluralistic, comprehensive company. The integrative business of Joincare includes invention, manufacture, selling and service of healthcare product. Among over 20 subsidiary companies, Joincare and Livzon have been listed on the market. At the end of 2019, around 13000 employees were working for the company, and the total asset of the company accounted for 25.438 billion yuan, of which the operating income reached 11.980 billion yuan.

NEWS

2020/08

Exploring the Blue Ocean Market of Inhalation Industry！Two Major Products Developed by Joincare Were Permitted to Produce

In the evening of 24th, Aug., Joincare Pharmaceutical Group Industry Co., Ltd (Joincare) has released the public notification that the company gained the ‘Drug Production License’ (DPL). Until now, the two major combination medicinal products developed by Joincare, Compound Ipratropium Bromide Solution for Inhalation and Levosalbutamol Hydrochloride Nebuliser Solution, have begun to be manufactured.

2019/05

One inhalation solution drug of Joincare obtained registration approval

Shanghai Securities News and cnstock news Joincare announced on the evening of April 9 that the Compound Ipratropium Bromide Solution for Inhalation developed by it has recently received the Drug Re

2020/12

Budesonide Suspension (Big Specification) Approved, Joincare Establishes Inhalable Drug Matrix

News from Cailian Press (Shenzhen, Reporter: Ding Rong): Joincare Pharmaceutical Group Industry Co., Ltd. (Joincare, 600380.SH) has seen new progress in its high-profile Budesonide Suspension for Inhalation. The Company recently received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for its drug named Budesonide Suspension for Inhalation (generic name), according to the announcement released by Joincare on the evening of December 10. A number of the Company's inhalable drugs have been approved, and this Budesonide Suspension for Inhalation (big specification) is projected to be a core product with a large market volume in line with its deployment at the early stage, a manager from Joincare told Cailian Press on the morning of December 11.

2020/12

Action Speaks for Responsibility, Joincare Wins Best Social Responsibility Award of "China ESG Golden Awards 2020"

The "Environment, Social Responsibility and Corporate Governance (ESG) Summit of Sina Golden Kirin Forum 2020", sponsored by finance.sina.com.cn, was held in the building of the Sina headquarters in Beijing on December 8. Under the theme of "Implementing an ESG Philosophy to Achieve the Sustainable Development Goals", this summit invited a number of excellent listed companies, institutional investors and authoritative media to bring together upstream and downstream resources of industrial development, connect ideas and resources, and unleash value and strength.

2020/11

Giving full play to the advantages of pharmaceutical health industry, Joincare has been awarded “Outstanding Contribution Award of Anti-epidemic”

On November 16, “the Best Listed Companies in Greater China in 2020” award ceremony hosted by Gelonghui was grandly held in Chengdu. Through screening layer by layer, Joincare Pharmaceutical Group Industry Co., Ltd. won “Outstanding Contribution Award of Anti-epidemic” from many candidate enterprises.

2020/10

Joincare (600380.SH): Meropenem for injection has passed the generic drug consistency evaluation

Gelonghui October 23 | Joincare (600380.SH) published that, recently, Shenzhen Haibin Pharmaceutical Co. Ltd. (hereinafter referred to as Shenzhen Haibin), the wholly-owned subsidiary of the Company, has received the Notice of Approval of Supplementary Drug Application approved and issued by National Medical Products Administration, that meropenem for injection produced by Shenzhen Haibin has passed the consistency evaluation of quality and curative effect of generic drug.